Expanding the use of dolutegravir-based antiretroviral therapy in multidrug-resistant TB

The wider availability of dolutegravir (DTG) containing HIVtherapy for patients livingwithmultidrug-resistantTB (MDR-TB) presents several advantages. DTG-based antiretroviral therapy (ART) has superior potency, reduces pill burden, and may reduce overall treatment-related toxicity, giving it the potential to improve outcomes in both diseases.While the uptake ofDTG-basedARTin programs where drug-resistant TB is treated remains unknown, there is early evidence from three programs that uptake is increasing. The use of DTG-based ART should be scaledup, beginning with antiretroviral-naive or virologically suppressed patients initiating MDR-TB treatment.